Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Company Deals

MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal

Fineline Cube Jan 10, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC

Fineline Cube Jan 11, 2026
Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Company Drug

GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan

Fineline Cube Nov 25, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...

Company Drug

China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial

Fineline Cube Nov 25, 2024

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...

Company Drug

J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis

Fineline Cube Nov 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...

Company Drug

Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas

Fineline Cube Nov 25, 2024

French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...

Company Drug

Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer

Fineline Cube Nov 25, 2024

China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...

Company Drug

Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Nov 25, 2024

China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...

Company Deals

Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 25, 2024

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...

Company Drug

MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program

Fineline Cube Nov 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 25, 2024

China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...

Company

Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation

Fineline Cube Nov 24, 2024

On November 22, China General Technology (Group) Holding released three official announcements through its official...

Company

Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation

Fineline Cube Nov 24, 2024

Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official...

Company

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline

Fineline Cube Nov 23, 2024

On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...

Company

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies

Fineline Cube Nov 23, 2024

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...

Company Drug

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC

Fineline Cube Nov 22, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...

Company Drug

First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors

Fineline Cube Nov 22, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...

Company Drug

Bayer’s Nubeqa Files for FDA Approval in mHSPC

Fineline Cube Nov 22, 2024

German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...

Company

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion

Fineline Cube Nov 22, 2024

The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...

Company Deals

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China

Fineline Cube Nov 22, 2024

China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...

Company Drug

China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors

Fineline Cube Nov 22, 2024

China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...

Posts pagination

1 … 201 202 203 … 606

Recent updates

  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
  • Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal
  • Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
  • Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Company Drug

Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Company Drug

Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.